We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Orthofix Medical Inc. (“Orthofix” or the “Company”) (NASDAQ: OFIX) in connection with the proposed acquisition of the Company by SeaSpine Holdings Corporation (“SeaSpine”) (NASDAQ: SPNE). Under the terms of the merger agreement, the Company’s shareholders will receive 0.4163 shares of SeaSpine common stock for each Orthofix share owned, representing implied per-share merger consideration of approximately $2.44 based upon SeaSpine’ October 13, 2022 closing price of $5.86. Upon completion of the transaction, Orthofix shareholders will own approximately 56.5 percent of the combined company, and SeaSpine shareholders will own approximately 43.5 percent of the combined company.
Weiss Law is investigating whether (i) Orthofix’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Orthofix’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.
September 26, 2023
We are investigating possible breaches of fiduciary duty and violations of the federal securities laws by, among others, the Board of Directors and senior officers of Origin Materials, Inc. (NASDAQ: ORGN) (“Origin” or the “Company”), concerning the Company’s business, operations, and prospects surrounding the construction of the Origin 2 commercial plant.
September 14, 2023
Weiss Law announces that on September 13, 2023, they filed a class action lawsuit in the United States District Court for the Southern District of New York (“Court”), captioned Zappia v. Myovant Sciences Ltd. et al. Case 1:23-cv-08097, on behalf of a class (“Class”) of individuals and entities that held common stock of Myovant Sciences, Ltd. (“Myovant”) as of the close of business on January 20, 2023 (“Class Period”), asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and Securities and Exchange Commission Rule 14a-9, in connection with the acquisition of Myovant Sciences, Ltd. by Sumitovant Biopharma Ltd. for an unfair price.
September 11, 2023
We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Hostess Brands, Inc. (“Hostess” or the “Company”) (NASDAQ: TWNK), in connection with its acquisition by The J. M. Smucker Company (NYSE: SJM) (“Smucker”) via tender offer.